Chesley Taft & Associates LLC Boosts Stake in Amgen Inc. $AMGN

Chesley Taft & Associates LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 14.6% during the 4th quarter, Holdings Channel reports. The fund owned 20,162 shares of the medical research company’s stock after purchasing an additional 2,565 shares during the period. Chesley Taft & Associates LLC’s holdings in Amgen were worth $6,599,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Brighton Jones LLC lifted its stake in shares of Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after purchasing an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC raised its holdings in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares in the last quarter. Schnieders Capital Management LLC. raised its holdings in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Amgen by 110.9% during the second quarter. American Century Companies Inc. now owns 165,122 shares of the medical research company’s stock valued at $46,104,000 after buying an additional 86,815 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC lifted its position in shares of Amgen by 15.2% during the second quarter. Elevation Point Wealth Partners LLC now owns 857 shares of the medical research company’s stock valued at $239,000 after buying an additional 113 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on AMGN. Truist Financial lifted their price objective on shares of Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research report on Thursday, January 8th. Guggenheim increased their target price on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research report on Friday, February 6th. Rothschild & Co Redburn lifted their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Daiwa Securities Group upped their price target on Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Finally, Sanford C. Bernstein lowered Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price objective for the company. in a report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $354.60.

Amgen Stock Performance

Shares of AMGN stock opened at $348.77 on Friday. The business has a fifty day moving average of $362.59 and a 200 day moving average of $330.22. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $188.01 billion, a price-to-earnings ratio of 24.51, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the company earned $5.31 earnings per share. The company’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.